BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Nov 05, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/2 cls
Charles River Laboratories International Inc. (NYSE:CRL) Jefferies David Windley Price target Hold 0% $39.44
Windley raised his target to $44 from $35 after Charles River reported 3Q12 EPS of $0.65, beating the $0.62 consensus estimate (see "EPS Watch," A22). In October, AstraZeneca plc (LSE:AZN; NYSE:AZN) named the tool supplier as its preferred outsourcing partner for regulated safety assessments and drug metabolism and pharmacokinetic development into 2015....

Read the full 532 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >